CRISPR Therapeutics AG (NASDAQ:CRSP) concluded the trading at $144.81 on Thursday, Jul 08, with a rise of 1.77% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $142.29 and 5Y monthly beta was reading 2.27 with its price kept floating in the range of $135.40 and $145.49 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that CRSP hit a high price of $220.2 and saw its price falling to a low level of $76.71 during that period. Over a period of past 1-month, stock came adding 21.78% in its value.
With its current market valuation of $11.03 Billion, CRISPR Therapeutics AG is set to declare its quarterly results on Jul 26, 2021- Jul 30, 2021. CRSP Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of $3.52 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.51 for 2021 with estimates of that growing to -$6.32 in next year. These estimates are suggesting current year growth of -0.9% for EPS and 11.39% growth next year.
In contrast, when we review CRSP stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 21 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 6 of them are recommending CRISPR Therapeutics AG (CRSP) as a Hold, while 14 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas 1 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the CRSP stock which is currently positioned at 0. It further provides that stock’s current price level is 5.74% away from its 20-day simple moving average and is 16.85% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 58.32 while volatility remained at 6.55% over the past week which changes to 5.42% when measuring it over the past month. Beta is valued at 2.27, while measure of average true range or ATR is currently at 8.18. In predicting price targets of as low as $117 and as high as $220, analysts are in agreement on assigning the stock over the next 12 months average price target of $163.11. Stock’s current price level is -19.2% above from estimated low price target while it is 51.92% below the estimated high; and even if the CRSP’s share succeeded to reach the median price of $165, then the outlook of +13.94% could come to the excitement of the investors.
In comparing CRISPR Therapeutics AG (CRSP)’s stock with other industry players reveals that stock’s current price change of +1.77% and that of +53.78% over the past 12 months is in better position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price fell by -0.67% in the last trading and went through an increase of 11.97% in past 12-month trading. Industry’s another major player Amgen Inc (AMGN) has jumped 0.44% up in previous session, but over the past year has faced a fall of -2.91%, while Moderna Inc (MRNA) was also up 1.77% however its price remained floating in the green at 53.78% over the same period. CRISPR Therapeutics AG has a P/E ratio of 0 against that of Bristol-Myers Squibb Company’s 0 while Amgen Inc is showing 20.23 for the same. On the other hand, the S&P 500 Index was down -0.86% in the last trading session while the Dow Jones Industrial closed the session lower at -0.75%.
Having a second look at CRISPR Therapeutics AG (NASDAQ:CRSP) provides that stock’s average daily trading volume for 3 months was 1.47 Million, while it jumped to 2.37 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 80.32 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 12.96% while it is 58.56% for the institutional holders. The figures also indicate that as of June 14, 2021, number of stock’s short shares was 3360000 which implies a short ratio of 3.34. This shows up a 4.18% of Short Interest in company’s outstanding shares on the day. In June the standing of shares short declined as it was 3.87 Million in the previous month. Drop of -5.42% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop.